Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus LEVATOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus LEVATOL.
LABETALOL HYDROCHLORIDE IN DEXTROSE vs LEVATOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
Labetalol is a nonselective beta-adrenergic antagonist with additional alpha1-adrenergic blocking activity. It competitively blocks beta1 and beta2 receptors and alpha1 receptors, leading to decreased heart rate, myocardial contractility, and systemic vascular resistance.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
50 mg orally once daily, increasing to 100 mg once daily after 2 weeks if tolerated; maximum 200 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Terminal elimination half-life is 6-8 hours; prolonged to 10-16 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Renal excretion accounts for 55-60% as unchanged drug; biliary/fecal elimination accounts for 40-45% as metabolites and unchanged drug.
Category A/B
Category C
Alpha/Beta-Blocker
Beta-Blocker